Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* confirmed and active CLL requiring treatment~* at least one previous treatment for CLL and having achieved a complete or partial remission/response but after a period of 6 or more months, shows evidence of disease progression~* fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours~* age 18yrs or older~* signed written informed consent~Key Exclusion Criteria:~* diagnosis of refractory CLL (failure to achieve a complete or partial remission/response or disease progression within 6 months of last anti-CLL treatment~* abnormal/inadequate blood values, liver and kidney function~* certain heart problems, serious significant diseases, AIHA, other current cancers or within the last 5 years~* active or chronic infections~* use of drugs to suppress allergic or inflammatory responses (glucocorticoids)~* CLL transformation~* CLL central nervous system involvement~* current participation in other clinical study~* inability to comply with the protocol activities~* lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab, Fludarabine, Cyclophosphamide (Type: EXPERIMENTAL): Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
- Fludarabine, Cyclophosphamide (Type: ACTIVE_COMPARATOR): Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).